Nuvalent (NASDAQ:NUVL) Reaches New 52-Week High – Here’s Why

Nuvalent, Inc. (NASDAQ:NUVL) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $123.70 and last traded at $123.72, with a volume of 671584 shares traded. The stock had previously closed at $123.60.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Truist Financial cut shares of Nuvalent from a “buy” rating to a “hold” rating and dropped their target price for the company from $140.00 to $124.00 in a research note on Tuesday, June 9th. Cantor Fitzgerald lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research note on Tuesday, June 9th. TD Cowen cut shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price target on the stock. in a report on Tuesday, June 9th. Canaccord Genuity Group downgraded Nuvalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 9th. Finally, Robert W. Baird set a $122.85 price objective on Nuvalent in a report on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvalent presently has a consensus rating of “Hold” and a consensus price target of $127.73.

Nuvalent Price Performance

The firm has a market capitalization of $9.77 billion, a PE ratio of -20.41 and a beta of 1.14. The company’s fifty day simple moving average is $109.07 and its 200 day simple moving average is $104.87.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period in the previous year, the firm posted ($1.18) EPS. On average, analysts anticipate that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the sale, the chief financial officer owned 85,533 shares in the company, valued at $8,441,251.77. This represents a 11.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James Richard Porter sold 30,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $103.77, for a total value of $3,113,100.00. Following the completion of the transaction, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at $33,712,693.83. The trade was a 8.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,523 shares of company stock valued at $11,409,713 over the last 90 days. 5.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvalent

A number of institutional investors have recently added to or reduced their stakes in NUVL. EverSource Wealth Advisors LLC grew its holdings in Nuvalent by 141.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Nuvalent in the third quarter valued at approximately $38,000. NBC Securities Inc. bought a new position in shares of Nuvalent in the fourth quarter valued at approximately $125,000. Finally, KBC Group NV grew its stake in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after acquiring an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.